18F-afatinib

N/A

Report date: 2026/05/13 20:02:10

NME

Base Information

Drug Name18F-afatinib

Drug Alias NameN/A

ClassificationRadiation-emitting productsSmall molecules > Heterocyclic drugs

Mechanisms of ActionEpidermal growth factor receptor erbB1 inhibitorsReceptor protein-tyrosine kinase erbB-2 inhibitorsReceptor protein-tyrosine kinase erbB-4 inhibitors +[5]

TargetsReceptor protein-tyrosine kinase erbB-4Receptor protein-tyrosine kinase erbB-2Epidermal growth factor receptor erbB1 +[5]

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryGermany

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesBoehringer Ingelheim International Gmbh

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesBoehringer Ingelheim International Gmbh

Active IndicationsN/A

Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A